Innate Pharma (IPHA) Interest Expenses (2019 - 2025)

Innate Pharma has reported Interest Expenses for 7 years, with the latest figure at -$3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 14.5% year-over-year to -$3.6 million; the trailing twelve-month figure through Dec 2025 stood at -$13.3 million (down 39.79% YoY), and the FY2025 full-year result was $3.6 million, down 14.5% from the prior year.
• Interest Expenses for Q4 2025 stood at -$3.6 million, down from -$3.2 million in the prior quarter.
• The five-year high for Interest Expenses was -$5428.7 in Q4 2022, with the low at -$6.6 million in Q2 2022.
• Historically, Interest Expenses has averaged -$3.1 million across 5 years, with a median of -$3.2 million in 2025.
• Annual changes were most pronounced in 2022 — Interest Expenses jumped 99.88% — and 2023, when it sank 36268.5%.
• Innate Pharma's Interest Expenses stood at -$4.6 million in 2021, then jumped by 99.88% to -$5428.7 in 2022, then slumped by 36268.5% to -$2.0 million in 2023, then tumbled by 115.14% to -$4.2 million in 2024, then rose by 14.5% to -$3.6 million in 2025.
• The last three Interest Expenses figures came in at -$3.6 million (Q4 2025), -$3.2 million (Q2 2025), and -$4.2 million (Q4 2024), per Business Quant data.